LY3541860 for Rheumatoid Arthritis
Trial Summary
What is the purpose of this trial?
The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.
Will I have to stop taking my current medications?
The trial requires that you do not change the dose of corticosteroids, opioids, or conventional disease-modifying antirheumatic drugs (cDMARDs) and that you do not take Janus kinase (JAK) inhibitors within 28 days before the screening MRI or during the study.
What data supports the effectiveness of the drug LY3541860 for treating rheumatoid arthritis?
Research Team
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
This trial is for adults with moderate to severe Rheumatoid Arthritis who haven't had enough improvement with at least one biologic or synthetic disease-modifying drug. Participants should be able to commit to a 50-week study period.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive LY3541860 intravenously for rheumatoid arthritis treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- LY3541860
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University